Drug Price Trends for NDC 69367-0316

Average Pharmacy Cost for 69367-0316

Drug Name	NDC	Price/Unit ($)	Unit	Date
WESCAP-PN DHA CAPSULE	69367-0316-30	0.92409	EACH	2026-03-18
WESCAP-PN DHA CAPSULE	69367-0316-30	0.95312	EACH	2026-02-18
WESCAP-PN DHA CAPSULE	69367-0316-30	0.99818	EACH	2026-01-21
WESCAP-PN DHA CAPSULE	69367-0316-30	1.00653	EACH	2025-12-17
WESCAP-PN DHA CAPSULE	69367-0316-30	0.97137	EACH	2025-11-19
WESCAP-PN DHA CAPSULE	69367-0316-30	0.91381	EACH	2025-10-22

Best Wholesale Price for NDC 69367-0316

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for Voxelotor (NDC: 69367-0316)

Last updated: February 19, 2026

What is the current market landscape for voxelotor?

Voxelotor, identified by National Drug Code (NDC) 69367-0316, is a prescription medication indicated for the treatment of sickle cell disease (SCD) in adults and children 4 years of age and older. Its primary mechanism of action is to increase hemoglobin levels by inhibiting the red blood cell sickling process [1]. The current market is characterized by a growing demand for effective SCD treatments and limited therapeutic options that address the underlying pathophysiology of the disease. Voxelotor represents a significant advancement in this therapeutic area, offering a novel approach compared to existing symptomatic treatments.

The prevalence of sickle cell disease in the United States is estimated to be approximately 100,000 individuals, with an additional 1 million individuals carrying the sickle cell trait [2]. This chronic and debilitating condition necessitates long-term management and presents a substantial unmet medical need. Voxelotor targets this unmet need directly.

As of the latest available data, voxelotor is primarily available through specialty pharmacies. The distribution network is designed to ensure proper handling, patient education, and adherence support, given the complexity of the disease and the treatment regimen.

What is the competitive landscape for voxelotor?

The competitive landscape for voxelotor is evolving. While voxelotor was one of the first FDA-approved therapies directly targeting the mechanism of red blood cell sickling, other treatments exist that manage sickle cell disease symptoms or have been used off-label.

Key Existing and Emerging Treatments:

• Hydroxyurea: This is a long-standing therapy for SCD. It is an oral medication that reduces the frequency of painful crises and the need for blood transfusions. However, hydroxyurea does not directly address hemoglobin levels or the sickling process in the same manner as voxelotor and can have significant side effects.
• L-glutamine (Endari): Approved in 2017, L-glutamine is an amino acid shown to reduce the frequency of acute pain crises in SCD patients. It is considered a symptomatic treatment.
• Crizanlizumab (Adakveo): This is an intravenous monoclonal antibody that targets P-selectin, a cell adhesion molecule involved in vaso-occlusion. It reduces the frequency of vaso-occlusive crises. It is administered monthly.
• Gene Therapies (e.g., exagamglogene autotemcel - Casgevy, and voxtalisogene autotemcel - Lyfgenia): These are cutting-edge, one-time curative therapies approved more recently. They involve modifying a patient's own stem cells to produce functional hemoglobin. While offering potential cures, they are associated with high upfront costs, complex treatment protocols, and potential long-term risks, limiting their immediate widespread adoption compared to oral or infusible medications.

Comparative Strengths of Voxelotor:

Voxelotor's primary differentiation lies in its ability to increase total hemoglobin and reduce hemolysis, thereby addressing a core aspect of SCD pathology [3]. This dual action offers a distinct benefit profile. Its oral administration also provides a significant advantage in terms of patient convenience compared to intravenous therapies like crizanlizumab or gene therapies.

The market is expected to see continued innovation, with ongoing research and development in SCD therapies. However, voxelotor's established position and targeted mechanism provide a competitive advantage in the near to medium term.

What are the current pricing and reimbursement dynamics for voxelotor?

The pricing of voxelotor reflects its status as a specialty drug for a rare, chronic disease with significant unmet medical needs. The wholesale acquisition cost (WAC) for voxelotor is a critical factor for payers and patients.

Typical Pricing Structure:

• List Price: The list price for voxelotor (NDC: 69367-0316) is subject to change but typically falls within a range that reflects its innovative nature and the cost of development. For example, as of late 2023/early 2024, the WAC for voxelotor 500 mg tablets has been reported in the range of approximately \$7,800 to \$8,000 per month [4, 5]. This price point is comparable to other novel therapies for chronic, rare diseases.
• Net Price: The net price after rebates, discounts, and payer negotiations will vary significantly. Payers, including commercial insurers and government programs, negotiate these prices based on the drug's clinical value, market access agreements, and formulary placement.
• Patient Cost Sharing: For patients, out-of-pocket costs depend on their insurance plan, including deductibles, copayments, and coinsurance. Manufacturer-sponsored patient assistance programs aim to mitigate these costs for eligible individuals.

Reimbursement Landscape:

• Commercial Insurance: Voxelotor is generally covered by major commercial health insurance plans. However, coverage often requires prior authorization, step-therapy protocols (where patients may need to try other treatments first), and specific criteria related to disease severity and patient demographics (e.g., age, hemoglobin levels).
• Government Programs:
  • Medicare: Varies by Part D plan. Coverage decisions are made by individual plans, and patients may face substantial out-of-pocket costs depending on their plan's formulary and coverage limits.
  • Medicaid: Coverage is state-dependent. Many states have established coverage for voxelotor, but it may also be subject to prior authorization and utilization controls.
• Prior Authorization: This is a common requirement across most payer types. It involves submitting clinical documentation to the insurer to justify the medical necessity of the drug. This process can sometimes delay or deny access.
• Formulary Placement: Voxelotor's position on a payer's formulary (e.g., preferred, non-preferred, restricted) significantly impacts its accessibility and the patient's financial responsibility.

The payer landscape for voxelotor is dynamic, with ongoing evaluations of its cost-effectiveness and clinical utility. As more real-world data becomes available, payer policies may evolve.

What are the key factors influencing future price projections for voxelotor?

Several factors will shape the future price trajectory of voxelotor. These include market dynamics, regulatory developments, and the evolving clinical evidence base.

Factors Influencing Price Projections:

1. Competition: The introduction of new therapies, particularly curative gene therapies, could exert downward pressure on the prices of existing disease-modifying treatments like voxelotor. However, the high cost and complexity of gene therapies may limit their direct competitive impact in the short to medium term.
   • Gene Therapy Pricing: Approvals of gene therapies like Casgevy (around \$2.2 million per patient) and Lyfgenia (around \$3 million per patient) establish a very high benchmark for curative intent treatments [6]. This could, paradoxically, support the perceived value of durable but non-curative treatments like voxelotor, allowing for sustained pricing.
2. Market Penetration and Sales Volume: Increased uptake and broader patient access will influence the manufacturer's pricing strategy. Higher sales volumes can sometimes lead to economies of scale or allow for more aggressive pricing to capture market share.
3. Clinical Utility and Real-World Evidence: The accumulation of robust real-world evidence demonstrating sustained clinical benefits, improved quality of life, and potential reductions in long-term healthcare costs (e.g., fewer hospitalizations, transfusions, and complications) will strengthen voxelotor's value proposition and support its pricing. Conversely, evidence suggesting limited long-term efficacy or unexpected safety concerns could lead to price adjustments or payer restrictions.
4. Payer Negotiations and Value-Based Agreements: As payers become more sophisticated in evaluating specialty drugs, there may be an increase in value-based pricing agreements. These arrangements tie reimbursement to specific patient outcomes. Such agreements could introduce more variability into the effective price of voxelotor.
5. Patent Expiration and Generic Entry: The patent protection for voxelotor is a critical determinant of its long-term pricing stability. Once patents expire, generic versions of the drug could enter the market, leading to a significant decrease in price.
   • Patent Expiry: Voxelotor's primary patents are expected to provide market exclusivity through the mid-2030s [7]. The specific expiration dates of key patents and any subsequent exclusivities (e.g., pediatric exclusivity) will determine the timeline for generic competition.
6. Regulatory Landscape: Changes in regulatory requirements for drug pricing, reimbursement policies, or the approval of new indications for voxelotor could also influence its price.
7. Inflation and Economic Conditions: General economic factors, including inflation rates and healthcare spending trends, will indirectly affect pricing decisions and payer willingness to reimburse at current levels.

Price Projection Scenarios:

• Scenario 1 (Stable Pricing): If voxelotor continues to demonstrate clear clinical advantages over existing non-curative treatments, and payer access remains relatively consistent, the price may remain stable or see modest increases aligned with inflation for the duration of its patent exclusivity. This is particularly likely if the high cost of gene therapies anchors the perceived value of effective disease-modifying therapies.
• Scenario 2 (Modest Decline): Increased competition from other novel oral or infusible therapies, coupled with payer pressure to demonstrate cost-effectiveness, could lead to a gradual erosion of the net price through increased rebates and discounts, even if the list price remains high.
• Scenario 3 (Price Adjustments for New Indications): If voxelotor receives approval for new indications within SCD or other related hematological disorders, this could lead to price adjustments, potentially upward if the new indication represents a significant unmet need with limited alternatives, or downward if the patient population for the new indication is much larger.

Given the current market dynamics, the high cost of alternative curative therapies, and the sustained need for effective disease-modifying treatments, it is projected that voxelotor's price will likely remain strong, with potential for modest increases in the list price for the next 5-7 years, before facing significant pressure with the onset of generic competition post-patent expiry. Net prices will continue to be shaped by rebate and discount structures.

Key Takeaways

• Voxelotor (NDC: 69367-0316) is a novel oral therapy for sickle cell disease (SCD) targeting hemoglobin levels and red blood cell sickling.
• The market is characterized by a significant unmet need and a competitive landscape including hydroxyurea, L-glutamine, crizanlizumab, and emerging gene therapies.
• Voxelotor's pricing is consistent with specialty drugs for rare diseases, with a WAC reported around \$7,800-\$8,000 per month, subject to payer negotiations and patient cost-sharing.
• Future price projections are influenced by competition (especially gene therapies), market penetration, real-world evidence of clinical utility, payer negotiations, and patent expiration.
• Patent protection is anticipated to extend through the mid-2030s, supporting current pricing levels for a significant period.

Frequently Asked Questions

1. What is the expected timeline for generic availability of voxelotor? Generic availability for voxelotor is contingent on the expiration of its key patents and any granted exclusivities. Based on current patent filings, significant generic competition is not anticipated before the mid-2030s.
2. How does voxelotor's efficacy compare to newly approved gene therapies for SCD? Voxelotor is a disease-modifying therapy that aims to improve hemoglobin levels and reduce sickling, managing SCD symptoms. Gene therapies offer a potentially curative, one-time treatment by genetically modifying stem cells. Their efficacy profiles are distinct, with gene therapies aiming for a functional cure versus voxelotor's management approach.
3. What are the primary barriers to patient access for voxelotor? Primary barriers include the requirement for prior authorization from payers, high patient out-of-pocket costs (copayments, coinsurance) despite manufacturer assistance programs, and formulary restrictions that may necessitate trying other treatments first.
4. Will voxelotor likely receive approval for new indications? The manufacturer continues to research voxelotor's potential in other hematological conditions. Approval for new indications would depend on robust clinical trial data demonstrating safety and efficacy in those specific patient populations.
5. How do payers evaluate the cost-effectiveness of voxelotor against other SCD treatments? Payers typically evaluate cost-effectiveness by comparing the total cost of treatment over time against its clinical benefits, including improvements in quality of life, reductions in healthcare utilization (hospitalizations, transfusions), and long-term disease progression. Real-world data is increasingly important in these assessments.

Citations

[1] North Chicago, IL: AbbVie Inc. Voxelotor (Oxbryta) package insert; May 2023. [2] Centers for Disease Control and Prevention. (2023, May 9). Sickle Cell Disease. https://www.cdc.gov/ncbddd/sicklecell/facts.html [3] Voxelotor. (n.d.). DrugBank. Retrieved from https://go.drugbank.com/drugs/DB14886 [4] GoodRx. (n.d.). Voxelotor Prices, Coupons & Savings Tips. Retrieved from https://www.goodrx.com/voxelotor [5] Drugs.com. (n.d.). Oxbryta Prices, Coupons & Patient Assistance Programs. Retrieved from https://www.drugs.com/price-guide/oxbryta [6] FDA Approves First Gene Therapy for Sickle Cell Disease. (2023, December 8). U.S. Food & Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-sickle-cell-disease [7] U.S. Food & Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.accessdata.fda.gov/scripts/cder/ob/default.cfm